Sonora Investment Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Sonora Investment Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$12K	Hold	439	–	–	﹤0.01%	749
2021 Q2	$13K	Buy	+439	New	+$12.7K	﹤0.01%	672
2019 Q1	–	Sell	-439	Closed	-$9K	–	1537
2018 Q4	$9K	Hold	439	–	–	﹤0.01%	916
2018 Q3	$11K	Hold	439	–	–	﹤0.01%	829
2018 Q2	$12K	Buy	439 +174	+66%	+$5.23K	﹤0.01%	737
2018 Q1	$8.16K	Buy	265 +65	+33%	+$2.09K	﹤0.01%	850
2017 Q4	$7.15K	Hold	200	–	–	﹤0.01%	895
2017 Q3	$5.51K	Buy	+200	New	+$4.85K	﹤0.01%	842

Other funds holding RVNC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Sonora Investment Management's RVNC Position: Q3 2021 in Review

Sonora Investment Management held its Revance Therapeutics, Inc. (RVNC) position steady in Q3 2021 at 439 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #749.

Sonora Investment Management first reported a position in RVNC in Q3 2017 and has held it in 8 quarters since. The position peaked at $13K in Q2 2021. 158 funds tracked by Wall St. Rank hold RVNC as of Q3 2021.

Sonora Investment Management held 439 shares of Revance Therapeutics, Inc. worth $12K as of Q3 2021.
Sonora Investment Management left its Revance Therapeutics, Inc. share count unchanged in Q3 2021.
Revance Therapeutics, Inc. made up ﹤0.01% of Sonora Investment Management's portfolio in Q3 2021, its #749 holding.
Sonora Investment Management first reported a position in Revance Therapeutics, Inc. in Q3 2017 and has held it in 8 quarters since.
Sonora Investment Management's Revance Therapeutics, Inc. position peaked at $13K in Q2 2021.
158 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2021.

Based on Sonora Investment Management's 13F filing for Q3 2021, filed 12 Nov 2021.